EP Patent

EP2621481B2 — Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases

Assigned to Exelixis Inc · Expires 2022-10-19 · 4y expired

What this patent protects

Patent listed against cabozantinib-s-malate.

Drugs covered by this patent

cabozantinib-s-malate (CABOZANTINIB S-MALATE)

Patent Metadata

Patent number: EP2621481B2
Jurisdiction: EP
Classification: —
Expires: 2022-10-19
Drug substance claim: No
Drug product claim: No
Assignee: Exelixis Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.